Shares of Telix Pharmaceuticals Limited (TLX) climbed 14% on Friday morning after the company reported strong revenue growth and issued an upbeat 2026 outlook despite posting a full-year loss.
The stock is currently trading at $7.66, up $0.95 or 14.16%, on the Nasdaq. The stock opened at $7.46 after closing Thursday at $6.71. The stock has traded between $6.34 and $30.36 in the past 52-week period.
However, revenue surged to $803.8 million from $516.6 million, driven by strong demand for Illuccix and the U.S. launch of Gozellix. For fiscal 2026, the company expects revenue of $950 million to $970 million, supporting investor optimism.
The company reported a loss of $7.13 billion for the year, compared to net income of $33.69 billion last year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.